Here are five observations:
1. The U.S. dominates the SCS global market, due to growing chronic back pain cases.
2. Supportive reimbursement and enhanced health service quality will drive the SCS market in the U.S.
3. Other geographic markets are struggling with a dearth of reimbursements.
4. The global SCS market will likely expand, owing to an increasing aging population, a growing obese population and rising healthcare expenditure.
5. Treatment’s costltiness, regulatory complications and traditional therapy competition will hinder global market growth, however.
More articles on devices:
Relievant Medsystems appoints Kevin Hykes CEO: 4 takeaways
Medovex launches facet joint syndrome relief device in Spain: 5 insights
Implanet reports 19% increase in spine revenue for 1st half of 2017: 7 key points
